Cancer Tissue Diagnostics Market Is Projected to Grow at A CAGR of 8.5% During the Forecast Period 2021-2031 - Comprehensive Research Report By FMI
DUBAI, United Arab Emirates, The global cancer tissue diagnostics industry is hugely driven by sheer number of biomarkers used for early cancer detection from blood or plasma, while prevalence of lung, breast and prostate cancers has been another constant driving factor to the demand growth. Despite getting battered by the outbreak of the COVID-19, the industry players are coming back to track with the increase in investment in research & development (R&D) activities and focus on launching wider variety of products.
The latest revised edition on ‘cancer tissue diagnostics’ market study by Future Market Insights (FMI) provides a holistic overview of the global industry along with thorough analysis of the demand-supply patterns, and growth & restraining factors during the forecast period of 2021 to 2031. According to the report, the cancer tissue diagnostics industry will expand at close to 8.5% CAGR, while North America, Western Europe, Asia Pacific, and Latin America will remain hotspots for stakeholders in this industry. As per the report, North America will have the highest market share, more than 40%, through 2031.
Request a report sample to gain comprehensive insights @
https://www.futuremarketinsights.com/reports/sample/rep-gb-4191
Key Takeaways from Study
- Rapid traction of immunohistochemistry (IHC) test to propel the demand growth
- The United States to maintain its lead in the world’s biggest cancer tissue diagnostics industry North America
- Germany to remain the major contributor to Western Europe cancer tissue diagnostics industry
- China and India remain lucrative in the APEJ (Asia Pacific Excluding Japan) cancer tissue diagnostics industry
- The United States, Japan, France, Italy, South Korea, and a few other countries to exhibit significant growth through 2031
For any Queries Related with the Report, Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-4191
How Rise in Cases of Cancer is Spearheading the Growth of Cancer Tissue Diagnostic Equipment Manufacturers?
According to the report on cancer published by the World Health Organization (WHO) on 3rd March, 2021, approximately 70% of deaths from cancer occur in low and middle-income countries, while cancer is the second leading cause of death globally and is responsible for approximately 10 million deaths per year. While this indicates the fatality and risks associated with cancer, it also signifies the importance of early diagnosis of cancer, which is resulting in growing adoption of timely diagnosis for various cancers such as lungs, breast, colon, and liver, to name a few.
The recent report by WHO states that late-stage presentation and lack of access to diagnosis and treatment are what make it more fatal for patients, while comprehensive treatment is reportedly available in more than 90% of high-income countries. Such reports are spreading awareness among people, which in turn is favoring the suppliers of cancer tissue diagnostics equipment.
We Offer tailor-made Solutions to fit Your Requirements, Request Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-4191
Who is Winning in this Space?
With the competition getting stricter, key players in the global cancer tissue diagnostics industry are embracing strategic ways to launch more effective products to target broader application areas. For instance,
- Abbott Laboratories launched its new products such as Vysis ALK Break Apart FISH Probe Kit, and others in the last 5 years
- Bio Rad Laboratories Inc. launched its new Liquicheck™ Tumor Marker Control equipped with 3 levels and 17 cancer antigens and popular tumor markers a couple of years back
More Valuable Insights
In its latest report, FMI offers an unbiased analysis of the cancer tissue diagnostics market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of test type (immunohistochemical (IHC) test (breast cancer, stomach (gastric) cancer, colorectal cancer, prostate cancer, and others) and in situ hybridization (ISH) test (breast cancer, non-small cell lung cancer (NSCLC), bladder cancer, and others)) across seven major regions of the world (North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA).
Explore FMI’s Extensive ongoing Coverage on Healthcare Domain
Cancer Antigens Market - This Cancer Antigens market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study.
Precision Cancer Imaging Market - The precision cancer imaging system market is expected to register a CAGR of 12% during the forecast period, up from US$ 67.8 Bn in 2022 to reach a valuation of US$ 210.58 Bn by 2032. Sales of precision cancer imaging system is expected to rise due to the rising awareness among the patients relating to molecular foundation of cancer and rising preference for personalized treatments.
Cancer-Focused Genetic Testing Services Market - Cancer-Focused Genetic Testing is prescribed by the physician to the patient who has history of cancer in their family. The risk of cancer in the future is diagnosed by performing the Cancer-Focused Genetic Testing. A panel test is performed for Cancer-Focused Genetic Testing to check the mutation of the gene.
About Future Market Insights (FMI)
About FMI:
Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/
Report: https://www.futuremarketinsights.com/reports/cancer-tissue-diagnostics-market